Cristal Therapeutics BV:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cristal Therapeutics BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10677
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cristal Therapeutics BV (Cristal Therapeutics) is a pharmaceutical company that develops nano-medicines for the treatment of cancer and chronic inflammatory disorders. The company develops CriPec docetaxel, a lead product candidate for solid tumours. It also provides peptide-based products, and CriPec dexamethasone for the treatment of arthritis. Cristal Therapeutics utilizes CriPec and CriPec ATN platform to develop nano-medicinal products. The company’s CriPec platform provides tuneable polymers and biodegradable drug linkers for the rational design and manufacturing of custom-made nano-medicines. It works in partnerships with biotech companies. Cristal Therapeutics is headquartered in Maastricht, the Netherlands.

Cristal Therapeutics BV – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cristal Therapeutics BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Cristal Therapeutics Raises USD14 Million in Venture Financing 10
Cristal Therapeutics Raises More than USD7.5 Million in Venture Financing 12
Cristal Therapeutics Raises Funds Through Venture Financing 14
Cristal Delivery Raises Funds Through Seed Financing Round 15
Partnerships 17
Cristal Therapeutics Enters into Agreement with iTeos Therapeutics 17
Cristal Therapeutics Enters into R&D Agreement with PX Biosolutions 18
Cristal Therapeutics BV – Key Competitors 19
Cristal Therapeutics BV – Key Employees 20
Cristal Therapeutics BV – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Corporate Communications 22
Aug 09, 2017: Cristal Therapeutics further strengthens its Scientific Advisory Board with appointment of Dr. Paul Lammers 22
Product News 23
10/24/2017: Dr. Istvan Udvaros joins Cristal Therapeutics as New Chief Medical Officer 23
Clinical Trials 24
Oct 24, 2018: Cristal Therapeutics initiates phase 2 clinical trial of innovative CriPec nanomedicine drug candidate in ovarian cancer 24
Nov 28, 2017: Cristal Therapeutics Awarded €2.5 Million Horizon 2020 Grant to Advance Its CriPec-docetaxel Through Phase 2 Trials 25
Nov 01, 2017: Cristal Therapeutics progresses nanomedicine CriPec-docetaxel to phase 1b development in patients with solid tumours 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Key Facts 2
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cristal Therapeutics BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cristal Therapeutics BV, Deals By Therapy Area, 2012 to YTD 2018 8
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cristal Therapeutics Raises USD14 Million in Venture Financing 10
Cristal Therapeutics Raises More than USD7.5 Million in Venture Financing 12
Cristal Therapeutics Raises Funds Through Venture Financing 14
Cristal Delivery Raises Funds Through Seed Financing Round 15
Cristal Therapeutics Enters into Agreement with iTeos Therapeutics 17
Cristal Therapeutics Enters into R&D Agreement with PX Biosolutions 18
Cristal Therapeutics BV, Key Competitors 19
Cristal Therapeutics BV, Key Employees 20

List of Figures
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cristal Therapeutics BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Cristal Therapeutics BV:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Exillon Energy Plc (EXI):企業の財務・戦略的SWOT分析
    Summary Exillon Energy Plc (Exillon) is an oil exploration and production company. The company explores, produces and develops crude oil. Its services include drilling, exploration, appraisal, development, operations, management, and production services. Exillon’s operating assets are located in two …
  • Kokubu Group Corp:企業の戦略・SWOT・財務情報
    Kokubu Group Corp - Strategy, SWOT and Corporate Finance Report Summary Kokubu Group Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Terex Corporation:企業のM&A・事業提携・投資動向
    Terex Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Terex Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Vaxart Inc (VXRT):企業の財務・戦略的SWOT分析
    Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Stagecoach Group plc:企業の戦略・SWOT・財務情報
    Stagecoach Group plc - Strategy, SWOT and Corporate Finance Report Summary Stagecoach Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Philippine Long Distance Telephone Co (TEL):企業の戦略的SWOT分析
    Philippine Long Distance Telephone Co (TEL) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • Humabs BioMed SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Humabs BioMed SA (Humabs), a subsidiary of Vir Biotechnology Inc, is an antibody therapeutics biotechnology company that discovers and develops human monoclonal antibodies. The company’s pipeline programs include Flu A virus, ebola virus, HBV, rabies virus, JCV, dengue, and others. It develo …
  • Fortune Electric Co Ltd (1519):企業の財務・戦略的SWOT分析
    Summary Fortune Electric Co Ltd (Fortune Electric) is a power company that manufactures and markets transformers and accessories. The company provides products such as distribution transformers, power transformers, cast resin transformers and amorphous metal alloy core transformers, among others. It …
  • Anavex Life Sciences Corp (AVXL):製薬・医療:M&Aディール及び事業提携情報
    Summary Anavex Life Sciences Corp (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, other central nervous system (CNS) diseases, pain and various types of cancer. The c …
  • Pernod Ricard SA (RI):企業の財務・戦略的SWOT分析
    Pernod Ricard SA (RI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • NU-Oil and Gas Plc (NUOG):企業の財務・戦略的SWOT分析
    Summary NU-Oil and Gas Plc (NU-Oil), formerly Enegi Oil Plc, is an independent oil and gas company that offers oil and gas exploration and production services. The company offers services such as exploration and development of natural gas, crude oil, and petroleum properties. It concentrates on acqu …
  • Nordstrom Inc (JWN):企業の財務・戦略的SWOT分析
    Nordstrom Inc (JWN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Valeant Canada LP-製薬・医療分野:企業M&A・提携分析
    Summary Valeant Canada LP (Valeant Canada), a subsidiary of Valeant Pharmaceuticals International Inc, is a pharmaceutical company that manufactures, markets and distributes pharmaceutical products. The company offers its products in various therapeutic areas, including pain management, neurology, c …
  • Varta AG (VAR1):企業の財務・戦略的SWOT分析
    Varta AG (VAR1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Genuine Parts Company:企業の戦略・SWOT・財務情報
    Genuine Parts Company - Strategy, SWOT and Corporate Finance Report Summary Genuine Parts Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Flowserve Corporation:企業の戦略・SWOT・財務分析
    Flowserve Corporation - Strategy, SWOT and Corporate Finance Report Summary Flowserve Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Iberdrola SA (IBE):電力:M&Aディール及び事業提携情報
    Summary Iberdrola SA (Iberdrola) is an energy utility. It constructs, operates, and manages power generation plants, transmission and distribution facilities, and other assets. The company produces electricity using conventional and renewable energy sources. Iberdrola also trades electricity and gas …
  • Oriental Yeast Co Ltd:企業の戦略・SWOT・財務情報
    Oriental Yeast Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Oriental Yeast Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Infinity Pharmaceuticals Inc (INFI):企業の財務・戦略的SWOT分析
    Infinity Pharmaceuticals Inc (INFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Synexus Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Synexus Ltd (Synexus), a subsidiary of Synexus Clinical Research Limited, is a site management organisation that offers patient recruitment and trial management services. The company services include feasibility assessment, project management, patient engagement, patient-centric clinical tri …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆